Algert Global LLC Nurix Therapeutics, Inc. Transaction History

Algert Global LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $18,792 - $28,684	2,160 Added 5.37%	42,371 $423,000
Q1 2023 May 12, 2023	BUY	$8.56 - $13.26 $119,043 - $184,406	13,907 Added 52.87%	40,211 $357,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $36,580 - $54,128	3,710 Added 16.42%	26,304 $289,000
Q3 2022 Nov 15, 2022	BUY	$12.33 - $19.81 $93,880 - $150,833	7,614 Added 50.83%	22,594 $294,000
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $118,042 - $222,003	14,980 New	14,980 $190,000
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $168,905 - $387,021	-13,053 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $12,157 - $15,870	-460 Reduced 3.4%	13,053 $378,000
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $306,880 - $495,791	13,513 New	13,513 $405,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.